Relapsed/Refractory AML
12
0
3
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
16.7%
2 terminated out of 12 trials
60.0%
-26.5% vs benchmark
17%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)